Circulating tumor DNA as a non-invasive tool to identify patients at risk for recurrence after chemoradiotherapy in stage III non-small cell lung cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 8553-8553
Author(s):  
Steven H. Lin ◽  
Xiayu Rao ◽  
Kimberly C. Banks ◽  
Ting Xu ◽  
Jianzhong He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
At Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Non Invasive ◽  
Patients At Risk ◽  
Tumor Dna

Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA

Lung Cancer ◽  
2018 ◽  
Vol 124 ◽  
pp. 154-159 ◽  
Author(s):  
Wey Cheng Sim ◽  
Chet Hong Loh ◽  
Grace Li-Xian Toh ◽  
Chia Wei Lim ◽  
Akhil Chopra ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Targeted Sequencing ◽  
Small Cell Lung ◽  
Non Invasive ◽  
Tumor Dna

scholarly journals Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yongliang Zhang ◽  
Yu Yao ◽  
Yaping Xu ◽  
Lifeng Li ◽  
Yan Gong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Chinese Patients ◽  
Plasma Samples ◽  
Small Cell Lung ◽  
Pan Cancer ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.

Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer

2014 ◽  
Vol 15 (6) ◽  
pp. 426-432 ◽  
Author(s):  
Gavitt A. Woodard ◽  
Matthew A. Gubens ◽  
Thierry M. Jahan ◽  
Kirk D. Jones ◽  
Jasleen Kukreja ◽  
...  
Keyword(s):  
Lung Cancer ◽  
At Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Molecular Assay ◽  
Small Cell Lung ◽  
Patients At Risk

scholarly journals P3.04-11 The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

2018 ◽  
Vol 13 (10) ◽  
pp. S925-S926
Author(s):  
R. Grinberg ◽  
L. Roisman ◽  
S. Geva ◽  
M. Lefterova ◽  
K. Quinn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document